| Filing date | Form | Description | Filing Group | View |
|---|---|---|---|---|
| SC 13G | A statement of beneficial ownership of common stock by certain persons |
Other
|
||
| SC 13D | Filing by person(s) reporting owned shares of common stock in a public company >5% |
Other
|
||
| SC 13D/A | An amendment to a SC 13D filing |
Other
|
||
| SC 13G | A statement of beneficial ownership of common stock by certain persons |
Other
|
||
| 4 | Statement of changes in beneficial ownership of securities |
3,4,5
|
||
| S-8 | Securities offered to employees pursuant to employee benefit plans |
Registration Statements
|
||
| S-8 | Securities offered to employees pursuant to employee benefit plans |
Registration Statements
|
||
| 8-K | Report of unscheduled material events or corporate event |
Current Reports
|
||
| 3 | Initial filing by director officer or owner of more than ten percent. |
3,4,5
|
||
| 3 | Initial filing by director officer or owner of more than ten percent. |
3,4,5
|
Data provided by Kaleidoscope.
GNI Group, Ltd. (2160:Tokyo) (“GNI Japan”) holds an indirect, controlling interest in Gyre Therapeutics, Inc. From time to time, GNI Japan will disclose historical and forward looking information, which will include information about our business. We may not have previously disclosed such information. Please refer to https://www.gnipharma.com/ir/yuho/ for GNI Japan’s Investor Information and Securities Reports.
